Crossmark

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price

Crossref DOI link: https://doi.org/10.1016/j.reumae.2019.10.007

Published Print: 2021-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

González Fernández, Mariángeles https://orcid.org/0000-0001-7678-8904
Villamañán, Elena https://orcid.org/0000-0001-6150-8471
Jiménez-Nácher, Inmaculada https://orcid.org/0000-0002-0680-5534
Moreno, Francisco https://orcid.org/0000-0002-6870-8174
Plasencia, Chamaida https://orcid.org/0000-0003-3503-9047
Gayá, Francisco https://orcid.org/0000-0003-3281-2559
Herrero, Alicia https://orcid.org/0000-0003-1375-5165
Balsa, Alejandro https://orcid.org/0000-0001-8070-7062
License Information

Text and Data Mining valid from 2021-06-01
More Information

This article is maintained by: Elsevier

Article Title: Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2019.10.007

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2019.10.004

Content Type: article

Copyright: © 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.